Monoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse
Journal Title: The AAPS Journal - Year 2006, Vol 8, Issue 2
Abstract
Drug abuse continues to be a major national and worldwide problem, and effective treatment strategies are badly needed. Antibodies are promising therapies for the treatment of medical problems caused by drug abuse, with several candidates in preclinical and early clinical trials. Monoclonal antibodies can be designed that have customized affinity and specificity against drugs of abuse, and because antibodies can be designed in various forms, in vivo pharmacokinetic characteristics can be tailored to suit specific clinical applications (eg, long-acting for relapse prevention, or short-acting for overdose). Passive immunization with antibodies against drugs of abuse has several advantages over active immunization, but because large doses of monoclonal antibodies may be needed for each patient, efficient antibody production technology is essential. In this minireview we discuss some of the antibody forms that may be effective clinical treatments for drug abuse, as well as several current and emerging production systems that could bridge the gap from discovery to patient use.
Authors and Affiliations
Eric Peterson, S. Michael Owens, Ralph L. Henry
Keywords
Related Articles
- EP ID EP681790
- DOI 10.1007/BF02854909
- Views 79
- Downloads 0
Permeability Comparison between Hepatocyte and Low Efflux MDCKII Cell Monolayer
Determination of passive permeability is not only important for predicting oral absorption and brain penetration, but also for accurately predicting hepatic clearance. High throughput (HT) measurement of passive permeabi...
Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials
Ajulemic acid (CT-3, IP-751,1’,1’-dimethylheptyl-Δ8 acid) (AJA) has a cannabinoid-derived structure; however, there is no evidence that it produces psychotropic actions when given at therapeutic d...
AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology
The first International Symposium of Nanomedicine on AIDS “AIDS Treatment with Novel Anti-HIV compounds Improved by Nanotechnology” was held November 19–20, 2009 in Beijing, China. This symposium...
microRNA and Cancer
MicroRNAs (miRNAs), a class of small, regulatory, non-coding RNA molecules, display aberrant expression patterns and functional abnormalities in human diseases including cancers. This review summarizes the abnormally exp...
Genotyping and drug response: Use of single nucleotide polymorphisms (SNPs) versus haplotypes to predict albuterol efficacy